BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117

Benzinga Newsdesk www.benzinga.com Positive 84.8%

Neg 0% Neu 0% Pos 84.8%

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.